Navigation Links
Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product
Date:5/15/2008

Date

59676-3100-1 Cartons containing six (6) D091534 07/2010

single dose vials of

PROCRIT(R) (epoetin alfa)

10,000 U/mL

59676-3200-4 Cartons containing four (4) P113612 09/2010

multidose vials of

PROCRIT(R) (epoetin alfa)

20,000 U/mL

59676-3400-1 Cartons containing four (4) P106803 06/2010

single dose vials of

PROCRIT(R) (epoetin alfa)

40,000 U/mL

17314-9600-1 Cartons containing 1 0717124 03/2009

DOXIL(R) (doxorubicin HCl

liposome injection) 20mg in

10mL (2 mg/mL) single use vial.

17314-9600-2 DOXIL(R) (doxorubicin HCl 0715423 02/2009

liposome injection) 50mg in

25mL (2mg/mL) single use vial

57894-0300-1 Cartons containing one (1) 8AM26021P1 01/2011

vial of REMICADE(R)

(infliximab) 100mg

57894-0300-1 Cartons containing one (1) 8BK35014P1 02/2011

vial of REMICADE(R)

(infliximab) 100mg

No other lot numbers of product are impacted by this incident. All three of these products have tamper-evident features that can be used to authenticate the package. Healthcare professionals and patients who have concerns about any product they possess may contact the number below for assistance with the identification of these features.

The amount of stolen and withdrawn product represents a very small proportion of the total product within the distribution channel; therefore the companies do not anticipate a disruption in product availability for patients.

JOM, Centocor, and
'/>"/>

SOURCE Ortho Biotech, L.P. and Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Ortho Evra Patch Makers Settling Cases
2. Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets
3. Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa)
4. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
5. ROBODOC(R) Emerges as a Curexo Technology Company at Upcoming Orthopaedic Surgeons Conference in San Francisco
6. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
7. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
8. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
9. Symmetry Medical to Present at Canaccord Adams Small-Cap Orthopedics Conference
10. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
11. Barr and Ortho Womens Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... SYDNEY , Aug. 31, 2015  US-Australian ... NVGN ) today confirmed its comprehensive scientific ... ground-breaking technology platforms in areas of unmet patient ... through the remaining preclinical projects prior to entering ... lead compounds. Acting Chief Executive Officer, ...
(Date:8/31/2015)... , Aug. 31, 2015 Trimb Healthcare AB ... to acquire YouMedical Group BV ("YouMedical"), a Dutch OTC ... total annual sales of approximately EUR 16 million, with ... "Our ambition is to build a leading ... step toward that goal. YouMedical gives us a stronger ...
(Date:8/31/2015)... ... ... Proove Biosciences, Inc. is a finalist for the Outstanding Tech Company category of ... its 22nd year, this premier awards event celebrates the best in Orange County’s technology ... world. The OC Tech Alliance will announce all winners at a gala dinner on ...
(Date:8/28/2015)... ... August 28, 2015 , ... Proove Biosciences , a ... International Spine Intervention Society’ s 23rd Annual Scientific Meeting (ASM). The ASM ... a focus on evidence-based research and clinical application, the event gathered industry thought ...
Breaking Biology Technology:Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4
... (Amex:,SGN) announced earlier today that breaking news will ... regarding the law firm of Vianale & Vianale, ... a life sciences company focused on the monitoring,detection ... Signalife uses its patented signal technology to design ...
... SAN DIEGO, Sept. 2 Halozyme Therapeutics,Inc. ... developing and,commercializing products targeting the extracellular matrix, ... Vice President,Research, Michael J. LaBarre, PhD, Vice ... President, Legal., "Halozyme is committed to ...
... Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that ... the Company is initiating a U.S.,Phase 2 ... in,combination with paclitaxel and carboplatin in patients ... or EGFR-activated tumours. The Principal,Investigator is Dr. ...
Cached Biology Technology:Signalife to Issue Breaking News Regarding Vianale & Vianale Tomorrow 2Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 2Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 3Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 4/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 2/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 3/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 4
(Date:8/4/2015)... ) today reported financial and operating results for the second quarter ... quarter contract revenue of $ 85.2 million, a ... of 26 % , Second quarter adjusted ... royalties in the current quarter , Operating cash ... to present another strong financial quarter, with all our divisions achieving ...
(Date:7/31/2015)... Den 10. internationale konference om Genomik (ICG-10, ... - 25. oktober i Shenzhen , ... i år. Siden starten i 2006 er ICB blevet ... og er en af de mest dynamiske, entusiastiske og ... nylige gennembrud og fremskridt inden for ,omik,-forskning, som yderligere ...
(Date:7/31/2015)... de julho de 2015 A 10 a. ... será realizada pela BGI de 22-25 de outubro de 2015, ... A conferência está celebrando seu 10 o. aniversário ... se tornou uma das reuniões mais influentes do mundo ... mais dinâmicos, entusiastas e prazerosos. A ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... Louis sheds light on one of the most important events ... years ago. No would-be colonizer could have survived on ... major threat for organisms accustomed to soaking in water. ... drying out might be provided by bryophytes, a group that ...
... of Minnesota have found that the hydrodynamic environment of fish ... available on the Journal of Experimental Biology Web ... for Earth-surface Dynamics. Catch a glimpse of a fish,s ... is. Tuna and mackerel look as if they should outpace ...
... the progression of advanced renal cell carcinoma (RCC), a form ... a new study published in the Journal of Clinical ... disease, but the outlook for patients has improved in the ... multiple pathways within cancer cells," study author Dr. Cora N. ...
Cached Biology News:Moss helps chart the conquest of land by plants 2Moss helps chart the conquest of land by plants 3Moss helps chart the conquest of land by plants 4Research finds water movements can shape fish evolution 2Promising results shown for kidney cancer drug 2